Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
19 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult male and female subjects of ages in the range over 19.
The subjects diagnosed with onychomycosis in up to 6 toenails at least
1 great toenail woth no fingernails
The subjects diagnosed with a mild to moderate onychomycosis (20% to 50% of surface of target nail without nail matrix infection or dermatophytoma)
The subjects having target nails less than 3mm in thickness and over 3mm in length
Positive indication on KOH Direct Microscopic Inspection on target nail
Positive dermatophyte or dermatophyte/candida on Fungi Cultivation Inspection on target nail
The subjects completely understood the clinical trial through detailed explanation presented, determined to participate in the clinical trial spontaneously, and agreed to observe precautions suggested thereby through written consent.
The subjects suffering other diseases that may cause nail abnormalities or are supposed to be affecting the assessment of the efficacy of study agent by the judgment of investigators
The subjects having a case history of hypersensitivity reaction to the component of Jublia® topical solution or Azole derivatives.
The pregnant, lactating, or fertile woman free from pertinent contraception